Aguilar P, Paessler S, Carrara A, Baron S, Poast J, Wang E
J Virol. 2005; 79(17):11300-10.
PMID: 16103182
PMC: 1193634.
DOI: 10.1128/JVI.79.17.11300-11310.2005.
Haahr S
Arch Gesamte Virusforsch. 1971; 35(1):1-9.
PMID: 5130442
DOI: 10.1007/BF01249747.
NATHANSON N, Cole G
Adv Virus Res. 1970; 16:397-448.
PMID: 4993221
PMC: 7131243.
DOI: 10.1016/s0065-3527(08)60028-7.
Bocci V, Russi M, RITA G
Experientia. 1967; 23(4):309-10.
PMID: 4964311
DOI: 10.1007/BF02135704.
Smillie J, Pusztai R, Smith H
Br J Exp Pathol. 1973; 54(3):260-6.
PMID: 4718268
PMC: 2072589.
Interferon system in mice infected with the scrapie agent.
Worthington M
Infect Immun. 1972; 6(4):643-5.
PMID: 4628902
PMC: 422586.
DOI: 10.1128/iai.6.4.643-645.1972.
Rabies vaccines and interferon.
Turner G
J Hyg (Lond). 1972; 70(3):445-53.
PMID: 4506993
PMC: 2130208.
DOI: 10.1017/s0022172400063026.
Target-organ treatment of neurotropic virus disease with interferon inducers.
Allen L, COCHRAN K
Infect Immun. 1972; 6(5):819-23.
PMID: 4404669
PMC: 422616.
DOI: 10.1128/iai.6.5.819-823.1972.
Effect of statolon-induced interferon on antibody formation.
Pindak F
Appl Microbiol. 1968; 16(7):1040-3.
PMID: 4298812
PMC: 547585.
DOI: 10.1128/am.16.7.1040-1043.1968.
The role of sialic acid in determining the survival of circulating interferon.
Bocci V, Pacini A, Pessina G, Bargigli V, Russi M
Experientia. 1977; 33(2):164-6.
PMID: 844537
DOI: 10.1007/BF02124043.
Interferon induction by radioprotective mercaptoalkylamines and derived thiophosphates.
Lvovsky E, Levy H, Doherty D, Baron S
Infect Immun. 1977; 15(1):191-6.
PMID: 188764
PMC: 421348.
DOI: 10.1128/iai.15.1.191-196.1977.
Effect of treatment with exogenous interferon, polyinosinic acid-polyctyidylic acid or polyinosinic acid-polycytidylic acid-poly-L-lysine complex on encephalomyocarditis virus infections in mice.
Olsen G, Kern E, Glasgow L, OVERALL J
Antimicrob Agents Chemother. 1976; 10(4):668-76.
PMID: 185951
PMC: 429812.
DOI: 10.1128/AAC.10.4.668.
